Use of oseltamivir in children

Canadian Family Physician

Volumn 55, Issue 12, 2009, Pages 1199-1201

  Jamieson, Blake ^a   Jain, Rini ^a   Carleton, Bruce ^a   Goldman, Ran D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CREATININE; OSELTAMIVIR; RIMANTADINE; SIALIDASE; ZANAMIVIR;

ABDOMINAL PAIN; BRAIN DISEASE; CANADA; CHEMOPROPHYLAXIS; CHILD; CONJUNCTIVITIS; CREATININE BLOOD LEVEL; DEHYDRATION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EAR DISEASE; EPISTAXIS; FLU LIKE SYNDROME; HUMAN; INFANT; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H1N1; KIDNEY FAILURE; MENTAL DISEASE; MULTIPLE ORGAN FAILURE; MYOCARDITIS; NAUSEA; PANDEMIC; PNEUMONIA; PRESCHOOL CHILD; PROPHYLAXIS; RECOMMENDED DRUG DOSE; RHABDOMYOLYSIS; SCHOOL CHILD; SEPTIC SHOCK; SHORT SURVEY; VOMITING; WORLD HEALTH ORGANIZATION;

ANTIVIRAL AGENTS; CANADA; CHILD; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; OSELTAMIVIR; PRACTICE GUIDELINES AS TOPIC;

EID: 73249123562     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (20)

1. Committee on Infectious Diseases. Policy statement - recommendations for the prevention and treatment of influenza in children, 2009-2010. Pediatrics 2009;124(4): 1216-26. Epub 2009 Sep 7.
2. Sugaya N, Nerome K, Ishida M, Nerome R, Nagae M, Takeuchi Y, et al. Impact of influenza virus infection as a cause of pediatric hospitalization. J Infect Dis 1992;165(2):373-5.
3. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004;(3):CD001269.
4. Gallaher WR. Towards a sane and rational approach to management of Influenza H1N1 2009. Virol J 2009;6:51.
5. Ismail I. Influenza A resistance to oseltamivir. Thorax 2009;64(9):828.
6. Centers for Disease Control and Prevention. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMRW Morb Mortal Wkly Rep 2009;58(16):433-5.
7. World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. Geneva, Switz: World Health Organziation; 2009. Available from: www.who.int/csr/resources/publications/ swineflu/h1n1-use-antivirals- 20090820/en/index.html. Accessed 2009 Nov 12.
8. Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Atlanta, GA: Centres for Disease Control and Prevention; 2009. Available from: www.cdc.gov/h1n1flu/ recommendations.htm. Accessed 2009 Oct 1.
9. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007;(1):CD002744.
10. US Food and Drug Administration [website]. Emergency Use Authorization (EUA) review: oseltamivir phosphate for swine influenza A. Silver Spring, MD; US Food and Drug Administration; 2009. Available from: www.fda.gov/ downloads/Drugs/ DrugSafety/InformationbyDrugClass/UCM153547.pdf. Accessed 2009 Nov 12.
11. Public Health Agency of Canada [website]. Interim guidance for emergency use of oseltamivir (Tamiflu® ) in children under one year of age in the context of 2009 (H1N1) pandemic. Ottawa, ON: Public Health Agency of Canada; 2009. Available from: www.phac-aspc.gc.ca/alert-alerte/h1n1/guidance- orientation-07-20-eng.php. Accessed 2009 Oct 27.
12. Okamoto S, Kamiya I, Kishida K, Shimakawa T, Fukui T, Morimoto T. Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J 2005;24(6):575-6.
13. Centers for Disease Control and Prevention. Emergency use authorization of Tamiflu® : fact sheet for health care providers. Atlanta, GA: Centres for Disease Control and Prevention; 2009. Available from: www.cdc.gov/h1n1flu/eua/pdf/tamiflu-hcp.pdf. Accessed 2009 Oct 1.
14. Peters PH, Moscona A, Schulman KL, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. Medscape J Med 2008;10(6):131.
15. Maxwell SR. Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 2007;334(7606):1232-3.
16. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008;31(12):1097-114. DOI: 10.2165/0002018-200831120-00006.
17. Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009;63(4):596-605.
18. Roche. Tamiflu® [Product Monograph]. In: Repchinsky C, editor-in-chief. Compendium of pharmaceuticals and specialties 2009. Ottawa, ON: Canadian Pharmacists Association; 2009. p. 2236-8.
19. World Health Organization. Pandemic (H1N1) 2009 - update 65. Geneva, Switz: World Health Organization; 2009. Available from: www.who.int/csr/don/2009-09-11/en/ print.html. Accessed 2009 Oct 1.
20. Centers for Disease Control and Prevention. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009;58(35):969-72.